Compare Pfizer Inc (PFE) vs Palantir Technologies Inc (PLTR) Price & Performance

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Palantir Technologies (PLTR) trades at $170.30, down 2.31% on the day but remains in a strong uptrend with recent earnings beats driving momentum. The stock shows robust fundamentals with 93% revenue growth in Q2 2026 and a 49% net income margin, though valuation metrics remain elevated with a P/E of 145.6. Technical indicators are neutral with support at $168 and resistance at $174, while the recent Nebius partnership strengthens Palantir's sovereign AI positioning.

Palantir's outlook remains positive with strong earnings momentum and strategic AI partnerships, though premium valuation and competitive pressures present risks. The consensus price target of $211.38 suggests 24% upside potential, supported by 50% analyst buy ratings. Key risks include valuation sustainability and compute capacity constraints as demand surges.